Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Thiotepa and Trastuzumab in HER2+ Breast Cancer With Leptomeningeal Metastasis
NCT07263425Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of thiotepa, trastuzumab in breast cancer, leptomeningeal metastasis (LM), sponsored by Jiangsu Provincial People's Hospital. Started Oct 2025; status: recruiting.
02
Drugs
thiotepatrastuzumab
03
Conditions
breast cancerleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT07263425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263425.